Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?

Lafferty RA, Flatt PR, Gault VA, Irwin N. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes? J Endocrinol
Insulin Resistance & Diabetes

Obesity drug shortages are symptomatic of wider malaise

Sumithran P, Finucane FM, Cohen RV. Obesity drug shortages are symptomatic of wider malaise Lancet

Weight Management with Orlistat in Type 2 Diabetes – An Electronic Healthcare Records Study

Ghosal S, Heron N, Mason K, Bailey J, Jordan K. Weight Management with Orlistat in Type 2 Diabetes – An Electronic Healthcare Records Study Br J Gen Pract

Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study

Craig HC, Alsaeed D, Heneghan H, Al-Najim W, Al Ozairi E, le Roux CW. Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study Int J Obes (Lond)

Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes

Bailey CJ, Flatt PR. Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes Peptides

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy

de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L, Hemmingway A, Ahmad NN, Bunck MC, Stefanski A. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy Hypertension

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Le Roux C, Mondoh A. Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play? Expert Opin Pharmacother

Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study

O'Donnell C, Crilly S, O'Mahony A, O'Riordan B, Traynor M, Gitau R, McDonald K, Ledwidge M, O'Shea D, Murphy DJ, Dodd JD, Ryan S. Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study Ann Am Thorac Soc

New therapies for obesity

Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity Cardiovasc Res

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Bailey CJ, Flatt PR, Conlon JM. Recent advances in peptide-based therapies for obesity and type 2 diabetes Peptides
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 Page2 Page3 … Page18 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI